4SCAR T cells
PreclinicalCell therapy
4SCAR T cells is one of 34 therapeutic programs targeting Breast Cancer. It is currently in Preclinical.
3
Indications
2
Total Trials
2
Active Trials
33
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Lexiscan
AstellasPreclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Tianeptine
PfizerPreclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
4SCAR T cells
SShenzhen Geno-Immune Medical Institute
Preclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for 4SCAR T cells. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy
- Highest Phase
- Preclinical[1]